FLOW HEALTH TECHNOLOGIES
CDSS Clinical Evidence Protocol
Version 2.0 | April 2026 | CONFIDENTIAL
CEP-CDSS-001 | Companion to TGA Pre-Submission Briefing v2
Flow Health Technologies Pty Ltd
Melbourne, Victoria, Australia
nippy2legend@gmail.com | flowhealthtech.com.au
Prepared by Dr Leon Xu, MD, BSc (Immunology and Microbiology)
Founder and CEO
CONFIDENTIAL
Versi
on
Date
Author
Changes
1.0
April 2026
Dr Leon Xu
Initial protocol -- three-phase evidence strategy, IMDRF N41 alignment,
demographic subgroup framework
2.0
April 2026
Dr Leon Xu
Site register corrected (Northern Health removed); Brunswick UCC added;
ANZCTR registration integrated; HREC applications cross-referenced;
classification updated to IIa/IIb; intended purpose aligned with Model Card;
equity floor (within-10pp) formalised; Justice Jump trigger table
cross-referenced; paediatric expansion pathway (RCH, 55 CPGs) added;
contact updated to nippy2legend@gmail.com
CONFIDENTIAL -- Flow Health Technologies Pty Ltd
Flow Health Technologies | CDSS Clinical Evidence Protocol | Confidential
Page 2
Table of Contents
1. Purpose and Regulatory Context
2. Intended Purpose Statement
3. Three-Phase Evidence Strategy
4. Demographic Subgroup Analysis Framework
5. Pilot Site Evidence Contributions
6. Brunswick UCC Pilot -- ANZCTR Registration
7. Paediatric Expansion Pathway
8. Clinical Governance and Principles
9. Justice Jump Trigger Integration
10. Ethics and Regulatory Approvals
11. Data Management and Privacy
12. Publication and Evidence Dissemination
13. Cross-Reference Register
CEP-CDSS-001 v2.0 | April 2026
nippy2legend@gmail.com
Flow Health Technologies | CDSS Clinical Evidence Protocol | Confidential
Page 3
1. Purpose and Regulatory Context
This protocol defines the clinical evidence generation strategy for the Flow Health Technologies Clinical
Decision Support System (CDSS), in support of Therapeutic Goods Administration (TGA) conformity
assessment under the Australian Register of Therapeutic Goods (ARTG). The CDSS is classified as IMDRF
Category III SaMD, proposed TGA Class IIa/IIb (under review following TGA pre-submission meeting request
lodged 6 April 2026), with IEC 62304 Class C software safety classification.
The protocol resolves TGA Pre-Submission Items 3 and 4 (demographic performance data; evidence strategy
acceptability) and aligns with the IMDRF Software as a Medical Device Clinical Evidence Framework (N41).
IMDRF Layer
Description
Flow Evidence Phase
Valid Clinical
Association
SaMD output associated with target clinical
condition
Phase 1: In Silico -- retrospective analysis
against 12M Australian ED presentations
Analytical Validation
SaMD accurately generates intended output
from input data
Phase 2: Shadow Mode -- prospective
concordance at approved pilot sites
Clinical Validation
SaMD achieves intended clinical purpose in
target population
Phase 3: Advisory Mode -- prospective
interventional deployment
2. Intended Purpose Statement
"Flow CDSS assists qualified healthcare professionals during triage and initial assessment of
undifferentiated presentations in urgent care and emergency settings. It does not provide
autonomous diagnoses."
The system provides: (a) a suggested ATS acuity category (1-5); (b) ranked differential diagnoses (Top-3); (c)
red-flag alerts for time-critical conditions (sepsis, anaphylaxis, NAI, DKA); (d) recommended initial clinical
pathway activation. All outputs require clinician review and acceptance before clinical action. The system does
not autonomously initiate treatment, modify patient records, or replace clinical judgment.
Intended Purpose Element
Evidence Required
Phase
ATS category suggestion
(1-5)
Concordance with clinician triage; sensitivity/specificity
per category; subgroup performance
1, 2, 3
Top-3 differential diagnoses
Diagnostic accuracy (final Dx in Top-3); comparison
against clinician initial impression
1, 2, 3
Red-flag alerts
Individual sensitivity >=90%, specificity per condition;
false-negative rate
1, 2, 3
Clinic

[Document continues...]

Cybersecurity Documentation
Flow Clinical Decision Support System (Flow CDSS)
CYB-CDSS-001 v2.1 | April 2026 | Confidential
Field
Detail
Document ID
CYB-CDSS-001
Version
v2.1
Date
April 2026
Status
ACTIVE — CONFIDENTIAL
Classification
CONFIDENTIAL
Product
Flow Clinical Decision Support System (Flow CDSS)
Manufacturer / Sponsor
Flow Health Technologies Pty Ltd, Brunswick, Melbourne, Victoria, Australia
Sponsor Role
Australian manufacturer acting as Sponsor per Therapeutic Goods Act 1989 (Cth) s 41BG
Contact
nippy2legend@gmail.com
Prepared by
Dr Leon Xu, MB BS, BSc (Immunology & Microbiology), Founder & CEO
Approved by
RA Lead, Flow Health Technologies Pty Ltd
Regulatory
TGA SaMD Class IIb | IMDRF Category III | IEC 62304 Class C
Regulatory Basis
TG(MD)R 2002 Schedule 1 Essential Principle 12.1(5) (cyber security of software-based
medical devices); IEC 81001-5-1:2021; TGA "Complying with medical device cyber security
requirements" (updated October 2025); TGA February 2026 AI/ML SaMD Guidance; IMDRF
N60:2020
ARTG Reference
Pending — Application in Preparation
Flow Health Technologies Pty Ltd — Confidential
Page 1
CYB-CDSS-001 v2.1 — Cybersecurity Documentation
FLOW HEALTH TECHNOLOGIES
Revision History
Version
Date
Author
Summary of Changes
v1.0
April 2026
Dr Leon Xu
Initial release for TGA submission
v2.0
April 2026
Dr Leon Xu
Reconciled per TGA Gap Analysis Resolution, 9 April 2026 — TGA Class
IIb confirmed; FLOW-CDSS acronym; contact updated to
nippy2legend@gmail.com; vulnerability disclosure email updated to
nippy2legend@gmail.com; CDS Hooks v1.0 confirmed in integration
interfaces; canonical document IDs updated throughout; EP
reference updated to EPC-CDSS-001 v2.0
v2.1
April 2026
Dr Leon Xu
TGA language alignment — Essential Principle references corrected to
TG(MD)R 2002 Schedule 1 numbering (EP 1, EP 2, EP 3, EP 4, EP 12.1(5),
EP 13); Sponsor role clarified per TGA s 41BG; TPLC approach
documented per TGA cybersecurity guidance; TGA "Complying with
medical device cyber security requirements" (October 2025) cited;
NDB Scheme references expanded with OAIC and Privacy Act Part
IIIC; ACSC Essential Eight baseline added; TGA mandatory reporting
obligations (s 41MP) cited in incident response; post-market
cybersecurity monitoring added to SDLC section; PMS-CDSS-001
v2.0 added to cross-references
Table of Contents
1. Purpose and Regulatory Basis
2. Cybersecurity Risk Management Approach
3. Threat Model
4. Cybersecurity Risk Register
5. Security Controls Implementation
6. Penetration Testing Plan
7. Vulnerability Disclosure Policy
8. Security Incident Response Plan
9. Cybersecurity in the Software Development Lifecycle
10. Document Control
1. Purpose and Regulatory Basis
Flow Health Technologies Pty Ltd — Confidential
Page 2
CYB-CDSS-001 v2.1 — Cybersecurity Documentation
FLOW HEALTH TECHNOLOGIES
1.1 Purpose
This Cybersecurity Documentation (CYB-CDSS-001) establishes the cybersecurity risk
management framework, threat model, security controls, and security assurance activities for the
Flow Clinical Decision Support System (Flow CDSS), a TGA Class IIb Software as a Medical Device
(SaMD).
This document demonstrates to the Therapeutic Goods Administration (TGA) that the Sponsor has
adopted a total product lifecycle (TPLC) approach to cybersecurity risk management, applying
state-of-the-art standards to meet the Essential Principles set out in Schedule 1 of the Therapeutic
Goods (Medical Devices) Regulations 2002 (Cth) ("TG(MD)R 2002"). It forms part of the technical
documentation required for inclusion of the device on the Australian Register of Therapeutic Goods
(ARTG).
1.2 Regulatory Basis
Standard / Requirement
Relevance
Therapeutic Goods Act 1989
(Cth), Chapter 4
Provides for the safety and satisfactory performance of medical devices; establishes
requirements for ARTG inclusion
TG(MD)R 2002, Schedule 1
— Essential Principles
Essential Principle 1 (use not to compromise health and safety); EP 2 (design for safety);
EP 3 (fitness fo

[Document continues...]

Flow Biophilic Urgent
Care Centre
Overview | April 2026 | Confidential
Flow Health Technologies Pty Ltd | Dr Leon Xu, MD, BSc (Immunology & Microbiology)
Australia's first biophilic-integrated Medicare Urgent Care Clinic — combining
evidence-based healing environments, proprietary AI clinical decision support, and
purpose-built digital infrastructure in a single, scalable model.
The National Context
The Australian Government has committed over $644 million to expand the Medicare UCC program from
87 operational sites to 137 clinics nationwide. Victoria plans 12 new UCCs in the 2025-26 budget cycle.
Over 1.3 million patient visits have been recorded since June 2023.
Despite rapid expansion, no existing UCC integrates biophilic design principles, AI clinical decision
support, or purpose-built digital infrastructure. Flow Health Technologies addresses this gap.
Austin Health's $275M ED expansion — Melbourne's largest — creates a parallel opportunity. The new
Austin ED will handle 30,000+ additional presentations/year. Flow has proposed a 90-day Shadow Mode
pilot with Florey Institute neuroscience research collaboration.
Flow Health Technologies Pty Ltd — Confidential
nippy2legend@gmail.com | flowhealthtech.com.au
Biophilic Urgent Care Centre — Overview
FLOW HEALTH TECHNOLOGIES
The Biophilic Difference
Biophilic design applies evidence-based connections to nature — living walls, natural materials,
optimised daylight, acoustic design, and views of greenery — to measurably improve outcomes.
Evidence
Source
Reduces hospitalisation time, mortality, pain, and stress for patients
Frontiers in Built Environment (2024)
Reduces burnout and enhances satisfaction for clinical staff
Frontiers in Built Environment (2024)
Real nature and natural daylight produce the strongest measurable effects
Frontiers in Public Health (2026)
Reduces cortisol, opioid requirements; improves circadian regulation
Frontiers in Public Health (2026)
Clinical Zone Mapping
Zone
Biophilic Intervention
Clinical Purpose
Reception & Triage
Living wall, natural materials, daylight
Reduces triage anxiety; accurate symptom
reporting
Treatment Bays
Natural light, views of greenery, acoustic
privacy
Supports assessment and wound evaluation
Waiting Areas
Natural materials, biophilic sound
Reduces perceived wait times and distress
Staff Areas
Natural light, acoustic privacy, restorative
materials
Reduces burnout; supports well-being
Flow CDSS — AI Clinical Co-Pilot
The Flow CDSS is a software-only medical device (IMDRF Category III SaMD, TGA Class IIb, IEC 62304
Class C) that analyses clinical data at the point of triage to provide:
•
ATS acuity category suggestion (1-5)
•
Ranked differential diagnoses (Top-3)
•
Red-flag alerts for time-critical conditions (STEMI, sepsis, stroke, PE, anaphylaxis) — sensitivity target
>= 90%
•
Clinical pathway activation recommendations
All outputs are advisory only. The clinician retains full decision authority at every stage. Canonical Intended Purpose locked
per RA-CDSS-001 Section 2.1 (5 April 2026).
Architecture & Deployment
•
Model: XGBoost GBT + ClinicalBERT (12-layer) + late-fusion MLP
•
Training data: 12 million de-identified Australian ED presentations
•
Integration: FHIR R4, CDS Hooks v2.0, HL7 v2 | Explainability: SHAP (top-5 factors)
•
CPG Library: 9 RCH Melbourne paediatric modules at launch, expanding to 55 by Q1 2027
Flow Health Technologies Pty Ltd — Confidential
Page 2
Biophilic Urgent Care Centre — Overview
FLOW HEALTH TECHNOLOGIES
Deployment Modes
Mode
Description
ARTG Scope
Shadow
CDSS runs in background; concordance data collected
Outside ARTG — QMS only
Advisor
Outputs visible; clinician retains full authority
Borderline — monitor under QMS
Active
Full integration; auto-write on acceptance
Within ARTG-listed SaMD config
Pilot Site Network
Site
Setting
n
Deployment
Status
Brunswick UCC
Flow-operated
Medicare UCC
TBD
Shadow > Advisor > Active
Primary; Q1-Q2 2027
Monash Casey ED
Public hospital ED
1,200
Shadow > Advisor
Approv

[Document continues...]

Five government-ready briefs covering:

1. Ministerial Brief — Executive summary for Minister Butler
2. Medicare UCC Site Designation — 6-step registration pathway
3. PHN Partnership Proposal — NWMPHN $250K grant
4. MRFF BioMedTech Application — $1.1-1.9M non-dilutive funding
5. TGA Regulatory Readiness — Classification and conformity status

Flow Health Technologies — Document Corpus
Catalogue Integration Update | 9 April 2026 | Batch Session-2026-04-09-A
Corpus Before
New Documents
Corpus After
Pillar
118
+1
119
Master I
New Registration
Document ID
FHT-CPG-CLIN-COMP-001
Version
1.0
Title
Flow CDSS — Clinician CPG Summary Compendium
Subtitle
9 RCH Clinical Practice Guidelines — Encoded for Clinical Decision Support
Filename
Flow_CDSS_Clinician_Summaries_All.pdf
Pages
22
Date
9 April 2026
Pillar
Master I (Clinic)
Audience
Clinicians — ED physicians, registrars, nurse practitioners
Classification
CANONICAL TEMPLATE — Clinician-Facing Guideline Format
Summary
Canonical reference compendium encoding 9 RCH paediatric clinical practice guidelines into structured
clinician-ready summaries. Each guideline follows a standardised format with ATS-mapped severity
tables, red flag escalation triggers, medication guidance, and disposition rules. Establishes the canonical
format for all future clinician-facing guideline summaries in the Flow CDSS.
Guidelines Covered (9)
• 1. Bronchiolitis (v2023-11)
• 2. Gastroenteritis (v2021-03)
• 3. Croup / Laryngotracheobronchitis (v2024-09)
• 4. Acute Asthma (v2023-07)
• 5. Febrile Seizures (v2026-02)
• 6. Head Injury / Paediatric TBI (v2020-12)
• 7. Abdominal Pain (v2024-04)
• 8. Fractures & MSK Injuries (v2024)
Flow Health Technologies — Corpus Catalogue Integration
Page 1
• 9. Viral URTI (v2024)
Canonical Format Sections
All future clinician-facing guideline summaries must follow this structure:
#
Section
1
Clinical Summary
2
Key Clinical Points
3
Trigger Criteria
4
Severity Classification & Management (ATS-mapped table)
5
Red Flags — Escalate Immediately
6
Not Recommended
7
Medications (condition-specific)
8
Disposition Rules (Admit / Discharge / Transfer)
9
Rehydration / Treatment Protocols (where applicable)
10
Source (hyperlinked to RCH CPG)
Cross-References
Document
Relationship
FHT-CPG-PAT-BRONCH-001
Patient-facing canonical template (paired output)
FHT-CPG-RCH-HV-001
Flow CPG webapp (deployed, 9 matching guidelines)
FHT-TGA-PSB v4.0 §3
CDSS output format referenced in TGA pre-submission
CEP-CDSS-001 §2
Clinical evaluation references CDSS output standards
RA-CDSS-001 §4
Risk analysis references guideline encoding fidelity
FHT-PILOT-ERH-PKG-001
Included as clinician_cpg_compendium_9_guidelines.pdf
FHT-EMR-PPT-001
Patient portal consumes paired patient-facing summaries
Corpus Pillar Totals (Post-Integration)
Pillar
Count
Description
Master I (Clinic)
4
Clinical outputs, guideline summaries, patient summaries
Master II (Platform)
46
Platform/technology, TGA regulatory, deployment, architecture
Master III (Policy)
2
Policy frameworks, governance
Bridge A (Index)
1
Master catalogue index, operational
Flow Health Technologies — Corpus Catalogue Integration
Page 2
Bridge B (Doctrine)
56
Legal, doctrine, academic, personal
Cross-Pillar
10
Cross-cutting documents spanning multiple pillars
TOTAL
119
Canonical Template Registry
Two canonical templates are now e

[Document continues...]

TECHNICAL ASSESSMENT | OFFICIAL — SENSITIVE
Flow Health Technologies | 9 April 2026
DIS Integration Assessment
LEAP × Flow Health — FHIR R4 / CDS Hooks Compatibility with Digital Victoria DIS Platform
Prepared for:
Chief Digital Officer, Victoria Police & Digital Victoria DIS Team
Prepared by:
Dr Leon Xu, MD — Flow Health Technologies
Date:
9 April 2026
Classification:
OFFICIAL — SENSITIVE
1. ASSESSMENT SCOPE
This document assesses the technical compatibility of Flow Health Technologies' LEAP integration layer with the Victorian Government
Digital Integration Service (DIS) platform. It covers three integration endpoints: FVISS health handover, MHWA crisis transport, and
forensic evidence linking. The assessment is structured for a joint technical review between Victoria Police Digital Services, Digital
Victoria, and Flow.
2. ARCHITECTURE OVERVIEW
LEAP
Mainframe
Tibco ESB
(existing)
→
→
DIS Platform
(Digital Vic)
→
FHIR R4 Gateway
(Flow)
→
Flow EMR
(Hospital)
The integration layer does not modify or replace LEAP. It reads from LEAP via the existing Tibco ESB, transforms data into FHIR R4 resources, and
exposes three scoped CDS Hooks endpoints. Victoria Police already uses the DIS platform for firearms registries, traffic monitoring, and family
safety systems — this integration follows the same pattern.
3. COMPATIBILITY MATRIX
Requirement
DIS Platform
Flow Layer
Transport protocol
REST / SOAP via Tibco ESB
REST (HTTPS / TLS 1.3)
Compatible
Data format
JSON / XML
FHIR R4 JSON (ndjson for bulk)
Compatible
Authentication
OAuth 2.0 / mTLS (DIS standard)
OAuth 2.0 + SMART on FHIR scopes
Compatible
API gateway
DIS API Management layer
CDS Hooks specification (HL7)
Compatible
Audit logging
DIS audit requirements
Per-field, per-exchange audit log
Exceeds
Data residency
Australian jurisdiction required
AU-hosted (SOC 2 Type II aligned)
Compatible
Encryption at rest
AES-256 (VPDSF requirement)
AES-256 (SQLite encryption ext)
Compatible
Real-time / async
Both supported (ESB patterns)
Sync REST + webhook callbacks
Compatible
HL7 v2 legacy support
Required for LEAP mainframe
HL7 v2 → FHIR R4 transformer
Requires mapping
VPDSF compliance
Mandatory
Assessment pending (pre-pilot)
Action required
Penetration testing
Annual requirement (AESCSF)
Not yet conducted
Pre-pilot action
4. ENDPOINT SPECIFICATION
GET /api/external/health-handover
Authority: FVISS
FVISS risk flags, active FVO summary, active warrants (boolean), recent FV incident count. No PII disclosed.
POST /api/external/crisis-transport
Authority: MHWA s.351/s.352
Creates transport record with legal authority, risk flags, officer observations. Returns LEAP-matched person flags.
POST /api/external/forensic-link
Authority: Crimes Act 1958
Binds LEAP incident event number to Flow clinical encounter. Returns person flags and incident metadata.
5. PRE-PILOT ACTIONS REQUIRED
Complete
DIS API registration — register Flow as an integration partner on the DIS platfo
Complete
FHIR R4 resource mapping — Patient, Enco

[Document continues...]

Flow Health Technologies
Educational & Workforce Alignment
Melbourne MD Pilot
Companion to RA-CDSS-001 | Version 1.0 | April 2026 | CONFIDENTIAL
This document maps the Flow CDSS platform to the four-year Melbourne MD curriculum, demonstrating
how each product module aligns with specific educational domains, learning activities, and assessment
touchpoints. It is structured as a teaching-infrastructure alignment tool — not a product pitch — and is
designed for review by Medical Education leadership, accreditation bodies, and clinical faculty.
Flow Health Technologies | Companion to RA-CDSS-001 | Version 1.0 | April 2026 | CONFIDENTIAL
Educational Workforce Alignment — Flow Health
Page 2
1. Domain Outcomes by Year
The following matrix shows how core biomedical and clinical domains progress from foundations to
near-intern level across the four-year Melbourne MD program.
Domain
Year 1 — Foundations
Year 2 — Application
Year 3 —
Specialisation
Year 4 — Integration
Anatomy &
Physiology
Gross & systems
anatomy; organ-system
physiology
Applied anatomy for
presentations (e.g.
dermatomes, coronary
territories)
Advanced
pathophysiology (HF
haemodynamics,
ventilation–perfusion)
Integrated
physiological reasoning
across organ systems
Biochemistry &
Pharmacology
Biochemical pathways;
drug classes &
mechanisms
Pathophysiology-linked
pharmacology
(bronchodilators,
antiplatelets, insulin)
Guideline-based
prescribing;
interactions, ADRs, dose
adjustment
Independent
prescribing at intern
standard;
polypharmacy
management
Clinical Skills &
Examination
History-taking; vital
signs; basic
examination
techniques
Focused examination
for core presentations
(chest pain, dyspnoea,
AKI)
Advanced examination:
paediatric, obstetric,
mental state
Full clinical assessment
with prioritisation &
handover
Investigation
Interpretation
Normal ranges; basic
FBC, U&E, CXR
interpretation
Pattern recognition
(troponin, TFTs, ABG,
ECG) linked to
presentations
Multistep investigation
pathways (CT-PA, echo,
lumbar puncture
indications)
Prioritised investigation
ordering; cost-effective
reasoning
Clinical Reasoning &
Management
Differential diagnosis
frameworks; illness
scripts
Presentation-based
reasoning (DKA,
seizures, chest pain,
dyspnoea)
Guideline application:
HF, ACS, COPD,
diabetes;
paediatric/obstetric
differences
Whole-patient
management;
escalation; discharge
planning; intern-level
autonomy
Professionalism &
Communication
Consent; ethics;
patient-centred
communication
foundations
Breaking bad news;
shared
decision-making; team
communication
Cultural safety;
medico-legal
awareness;
interdisciplinary
collaboration
Leadership in clinical
handover; error
disclosure; professional
identity formation
Flow Health Technologies | Companion to RA-CDSS-001 | Version 1.0 | April 2026 | CONFIDENTIAL
Educational Workforce Alignment — Flow Health
Page 3
2. CDSS-Enabled Learning Activities
Flow is positioned as a teaching infrastructure integrated into existing curriculum delivery — not a
replacement for clinical teaching. The table below maps each Flow module to specific learning activities
and assessment touchpoints across the four years.
Years 1–2: Simulated and De-Identified Data Only
• Physiology teaching using the Flow EMR vitals grid to visualise abnormal physiology in real-world-style
traces.
• Clinical skills and presentations using CPG-as-Code (e.g. chest pain, dyspnoea, fatigue) as structured
differential frameworks for exam-style cases.
• Investigation interpretation via Flow CDS Hooks cards (how FBC, U&E, troponin, TFTs trigger different
clinical paths).
• Guideline application using the Flow CPG engine to make students walk guideline logic (HF, ACS, COPD,
diabetes) step-by-step.
Years 3–4: Supervised Clinical Deployment
• Prescribing refinement using the Flow Rx Pad for interaction checking, ADR prompts, and weight-based
dosing in simulated patients.
• Paediatric and obstetric differences: same presentations, different guideline branches via CPG Engine +
CDS Hooks.

[Document continues...]

Austin Health Pilot Package includes:

• Flow CPG Web App (PWA) — 9 RCH clinical practice guidelines
• Flow Document Generator — 6 clinical document templates
• 90-Day Pilot Model: Phase 1 CPG PWA (Day 1), Phase 2 Shadow (90 days), Phase 3 Advisory (90 days)
• Site: 145 Studley Road, Heidelberg VIC
• EMR: Cerner Millennium (FHIR R4)
• Contact: Prof Christine Kilpatrick (CEO)

CASE SUMMARY
Leon Xu v. Australia
Case: Leon Xu v. Australia
Author: Dr Leon Xu, MD, BSc (Immunology & Microbiology)
Date: 6 April 2026
Status: Active — CRPD Communication submitted 1 April 2026; MHWC and VEOHRC
complaints filed; Community Treatment Order ongoing
1. PARTIES
Claimant: Leon Xu, Australian national, doctor and researcher, founder of Flow
Health Technologies Pty Ltd.
Respondent: The State of Victoria (through Northern Health) and the
Commonwealth of Australia (as State party to the Convention on the Rights of
Persons with Disabilities).
2. FACTUAL SUMMARY
The claimant was subjected to three involuntary apprehensions in 23 days:
(a) 6 March 2026 — Assessment Order (MHWA s.101) issued by social worker
Mania Stevens at the Northern Health Merri-bek Clinic without any direct clinical
examination. The order was based solely on unverified family collateral. The
claimant was detained at Northern Hospital from 6 to 12 March 2026.
(b) 17 March 2026 at 7:51 PM — While asleep at home (288 Albert Street,
Brunswick). Two paramedics and two unidentified individuals attended. The
paramedics climbed onto the balcony without consent. The claimant was
transported under a Temporary Treatment Order signed by Dr Ram Kumar
Nadella. He was detained on Ward 23, Northern Hospital.
(c) 29 March 2026 — Police entered the apartment through an unlocked door
without knocking or announcing their presence. The claimant was escorted
back to Northern Hospital while on an existing Temporary Treatment Order.
(d) 1 April 2026 — Mental Health Tribunal hearing (Case Ref: HN-2026-05792).
The claimant was discharged from inpatient detention. The Temporary
Treatment Order was converted to a Community Treatment Order. Liberty
remains restricted.
(e) Compulsory medication: Olanzapine administered without informed consent
despite the claimant’s documented Advance Statement of Preferences
objecting to this medication on evidence-based clinical grounds.
3. CAUSES OF ACTION
(a) CRPD Articles 12, 14, 15, 17, 19, 25 — submitted to the Committee on the
Rights of Persons with Disabilities on 1 April 2026.
(b) Victorian Charter of Human Rights and Responsibilities Act 2006, sections
10 (protection from degrading treatment), 13 (privacy and home), 21 (right to
Case Summary — Leon Xu v. Australia
1
liberty), 22 (humane treatment when deprived of liberty).
(c) Equal Opportunity Act 2010 (Vic), sections 6, 8–9 — disability
discrimination.
(d) Mental Health and Wellbeing Act 2022 (Vic) — procedural breaches: s.142
(assessment criteria not met without direct examination), s.232 (paramedics
lacked authority following the 2023 Amendment), ss.228/230 (transport
hierarchy violated).
(e) Common law — false imprisonment, trespass to the person, breach of
statutory duty.
4. HARM SUFFERED
(a) Physical liberty: 26 days total inpatient detention (6–12 March = 7 days;
17–29 March = 12 days; 29 March–1 April = 3 days), plus ongoing Community
Treatment Order restrictions.
(b) Bodily integrity: Compulsory administration of olanzapine without consent
— the antipsychotic with the highest metabolic risk profile, incompatible with
Long COVID and professional functioning.
(c) Psychological harm: Three forced entries to the claimant’s home, including
being woken from sleep (17 March), balcony intrusion, and unannounced police
entry (29 March). Fear, humiliation, hypervigilance. Repeated disruption of
sense of safety in own home.
(d) Professional harm: Disruption to work as doctor and researcher. Disruption
to Flow Health Technologies (startup founder — missed critical development
and investor engagement windows during detention). Reputational harm from
involuntary psychiatric detention.
(e) Autonomy violation: Advance Statement of Preferences disregarded. Will
and preferences overridden by substituted judgment.
(f) Housing and personal: Forced removal from home on three occasions.
Disruption to tenancy, personal relationships, and daily life.
5. COMPENSATION CLAIM
The claimant seeks financia

[Document continues...]

COMPENSATION PACKAGE
Leon Xu v. Australia
CRPD Communication No. [2026] | MHWC Complaint | VEOHRC Complaint
Dr Leon Xu, MD, BSc (Immunology & Microbiology)
Founder & CEO, Flow Health Technologies Pty Ltd
9 April 2026 — Melbourne, Victoria, Australia
Status: Active — CRPD Communication submitted 1 April 2026
CONFIDENTIAL — Without Prejudice
1
SCHEDULE OF VIOLATIONS
The following table sets out a chronological record of each violation, the statutory or rights basis
of the breach, and the category of harm sustained by the claimant.
Date
Event
Breach
Harm
6 March 2026
Assessment Order issued by social worker
Mania Stevens at Northern Health Merri-bek
Clinic without any direct clinical examination.
Based solely on unverified family collateral.
MHWA s.142 (assessment
criteria); CRPD Art. 12, 14
Liberty, autonomy,
dignity
6–12 March
2026
Detained at Northern Hospital — 7 days
False imprisonment; Charter
s.21 (liberty), s.22 (humane
treatment)
Physical liberty,
psychological
harm
14 March 2026
MHWC Complaint lodged
—
Procedural step
15 March 2026
VEOHRC Complaint filed
—
Procedural step
17 March 2026,
7:51 PM
While asleep at home (288 Albert Street,
Brunswick). Two paramedics + two
unidentified individuals attend. Paramedics
climbed onto balcony without consent.
MHWA s.232 (paramedics
lacked authority per 2023
Amendment); ss.228/230
(transport hierarchy violated);
Charter s.13 (privacy/home)
Privacy, dignity,
psychological
harm, home
invasion
17–29 March
2026
Detained on Ward 23, Northern Hospital
under TTO signed by Dr Ram Kumar Nadella
— 12 days
False imprisonment; CRPD
Art. 14; Charter s.21
Physical liberty,
psychological
harm
26 March 2026
Formal Statement of Treatment Preferences
filed — objecting to olanzapine on
evidence-based clinical grounds
MHWA s.65 (ASP)
Procedural step
During
detention
Olanzapine administered without informed
consent despite documented ASP objection
MHWA s.65 (ASP
disregarded); CRPD Art. 12,
15, 17, 25
Bodily integrity,
autonomy
29 March 2026
Police entered apartment through unlocked
door without knocking or announcing
presence. Escorted back to Northern
Hospital.
Charter s.13 (privacy/home);
potential unlawful entry
Privacy, dignity,
psychological
harm
29 March – 1
April 2026
Detained at Northern Hospital — 3 days
False imprisonment; CRPD
Art. 14
Physical liberty
1 April 2026
Mental Health Tribunal hearing
(HN-2026-05792). Discharged from
inpatient. TTO converted to Community
Treatment Order.
CRPD Art. 12 (legal capacity);
Art. 14 (liberty)
Ongoing liberty
restriction
1 April 2026
CRPD Individual Communication submitted to
OHCHR
—
Procedural step
CONFIDENTIAL — Without Prejudice | Leon Xu v. Australia | 9 April 2026
2
Total detention: 26 days across 3 apprehensions in 23 days.
2
COMPENSATION SCHEDULE
The following schedule sets out the four heads of damage claimed, with itemised calculations and
reference to applicable legal precedent.
HEAD A — General Damages (Pain, Suffering, Loss of Amenity)
Claimed range: $150,000 — $250,000
Item
Basis
Amount
Loss of liberty — 26
days detention
At $3,000–$5,000/day (consistent with Australian precedent:
Spautz $1,339/day for 56 days; Stradford $309K for 7 days
(~$44K/day); MZZHL $350K for ~730 days (~$480/day for
long detention))
$78,000 — $130,000
Three forced home
entries
Balcony climb (17 March); unannounced police entry (29
March); initial removal (6 March). Each constitutes trespass to
the person and invasion of privacy.
$30,000 — $45,000
Psychological
distress
Fear, humiliation, hypervigilance, loss of sense of safety in own
home. Three forced entries including being woken from sleep.
$25,000 — $40,000
Loss of bodily
integrity
Forced olanzapine — highest metabolic risk antipsychotic,
incompatible with Long COVID, administered without consent
despite ASP objection.
$15,000 — $30,000
Ongoing CTO
restrictions
Continuing restriction of liberty under Community Treatment
Order since 1 April 2026.
$2,000 — $5,000 (to date,
accruing)
Precedent
MZZHL v Commonwealth [202

[Document continues...]